Type II Diabetes Mellitus
Conditions
Brief summary
Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue. Moreover, in adipose tissue mitochondrial dysfunction results in decreased fatty acid oxidation and triglyceride synthesis, leading to increased circulating fatty acid concentrations, which in turn also leads to lipid accumulation inside muscle tissue. Lipid accumulation inside muscle tissue interferes with the insulin signaling pathway and causes insulin resistance. Mitochondrial dysfunction in both tissues has therefore been proposed to play an important role in insulin resistance in humans. Pioglitazone, a thiazolidinedione, is an FDA approved medication for the treatment of type 2 diabetes. It improves muscle insulin sensitivity at least in part by lowering intramuscular lipid concentrations but the mechanism by which this occurs is unclear. In the present study, we shall therefore test the hypothesis that pioglitazone improves mitochondrial function in muscle and adipose tissue in humans who are insulin resistant.
Interventions
OTHERpioglitazone
Sponsors
Takeda
Arizona State University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. 2. Subjects may be of either sex with age as described in each protocol. Female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period. 3. Subjects must range in age from 18-65. 4. Subjects must have the following laboratory values: * 2-hour OGTT plasma glucose 140-250 mg/dl * Hematocrit ≥ 35 vol% * Serum creatinine ≤ 1.6 mg/dl * AST (SGOT) \< 2.5 times upper limit of normal * ALT (SGPT) \< 2.5 times upper limit of normal * PT, PTT within the normal range
Exclusion criteria
1. Subjects must not be receiving any medications with known effects on glucose tolerance unless the subject has been on stable dose of such agents for the past three months before entry into the study. Subjects taking systemic glucocorticoids will be excluded. Subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months. 2. History of clinically significant heart disease, including ischemic heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the EKG) and congestive heart failure 3. History of peripheral vascular disease (history of claudication) 4. History of pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation). 5. History of peripheral edema 6. Uncontrolled hypertension with systolic BP\>160 mmHg, diastolic BP\>100 mmHg 7. Resting heart rate \>100 beats/min 8. Autonomic neuropathy 9. Heavy alcohol consumption (\> 2 drinks/day)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of adipocyte mitochondria | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| number of adipocyte proteins | 3 months |
| number of mitochondrial proteins | 3 months |
Countries
United States
Outcome results
None listed